Trial Profile
Phase I Study for Tolerability, Pharmacokinetics, Immunogenicity, Safety of Dose Escalation and Preliminary Efficacy of GR1405 in Patients with Advanced solid tumor and lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs GR 1405 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Chongqing Genrix Biopharmaceutical; Genrix (Shanghai) Biopharmaceuticals
- 25 Oct 2018 New trial record